Developing a successful market access strategy requires navigating complex global payer and health technology assessment (HTA) requirements, often across product classes and therapeutic areas. Our Value & Access Consulting experts work to provide actionable strategies to drive and demonstrate payer value throughout the development lifecycle to maximize a product’s success in today’s competitive market. Our experienced team leverages deep relationships with HTA bodies and payers in established and emerging markets to understand what shapes decision making and applies these insights to overcome payer challenges and ensure optimal pricing and access.
We Can Help You
- Identify market and stakeholder requirements for your asset
- Optimize HTA and payer acceptance with the right evidence
- Engage early with multiple stakeholders for insight into your development planning
- Develop evidence to support rapid and broad commercial uptake at launch
- Establish an integrated evidence plan beyond your clinical development plan
- Optimize your asset value
- Ensure your development plan aligns with investor requirements
- Align your asset investment strategy with investor exit-strategy goals
- Optimize time and cost of development with strategic value and access evidence planning
- Identify the right patient-centric and real-world evidence needed for your product development strategy
We Offer You
Global pricing and market access strategy and roadmaps
Value and evidence strategy and planning
Integrated scientific advice for evidence generation optimization for both regulatory and market access
Payer advisory boards and engagement plans to explore key market access hypotheses
Value story development and testing with relevant stakeholders
Cross-functional team alignment through market access workshops
In-licensing decision support
Strategy development and implementation for country-specific pricing and reimbursement or formulary submissions, including AMCP dossier and HTA submissions
Value and access launch support through our framework to integrate key internal and external drivers for initial and continued commercial success
Experienced Value & Access Experts
Our dedicated Value & Access team brings more than two decades of leadership and deep experience to every project including:
A Pricing and Reimbursement Policy Council (PRPC) comprised of a diverse group of industry experts, providing insights into the latest issues, trends, and changes affecting market access
A track record of influence having supported HTA and regulatory submissions to AIFA, AEMPS, NICE in the UK, G-BA in Germany, HAS, TLV in Sweden, CADTH, EUnetHTA and others, including more than 45 formal integrated scientific advice engagements
*AIFA = Italian Medicines Agency; AEMPS = Spanish Agency of Medicines and Medical Products; NICE = National Institute for Health and Care Excellence; G-BA = Federal Joint Committee; HAS = National Authority for Health; TLV = Dental and Pharmaceutical Benefits Agency; CADTH = Canadian Agency for Drugs and Technologies in Health; EUnetHTA = European Network for Health Technology Assessment
Strong relationships with HTA bodies and payers in both established and emerging markets
Expertise and experience in over 45 countries and across all major therapeutic areas
In-house expertise and no outsourcing, with ~35,000 payer interviews and all value story and dossier writing done internally
Rigorous quality standards applied to all content development
Value & Access Consulting Resources
Value & Access Consulting Experts
